Article citationsMore>>
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., Muller, M.A., et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181, 271-280.
https://doi.org/10.1016/j.cell.2020.02.052
has been cited by the following article:
-
TITLE:
SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research
AUTHORS:
Jinguo Zhu
KEYWORDS:
COVID-19, SARS-CoV-2, Pulmonary Injury, Clinical Manifestation, Treatment Strategies
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.12 No.3,
March
31,
2022
ABSTRACT: The SARS-CoV-2 has infected over 194,909,000 cases and over 4,170,000 deaths in the world before the end of July 2021. The virus attacks human alveoli and induces severe lung injury (COVID-19 disease) and spreads rapidly. The mechanisms of COVID-19 disease are unclear. To better understand this disease, This review analyzes the SARS-CoV-2 biological characteristics, insights the effect of alveolar epithelium and its adjacent microvascular endothelium, investigates human host cells immune response and immunothrombosis. Explains clinical manifestations of COVID-19 associated lung injury. It may be helpful for development management strategies for COVID-19 associated pulmonary damage.
Related Articles:
-
Kassim F. Adebambo, Nadia Haji
-
Asmaa Meraou, Hafida Merzouk, Amel Saidi, Amel Medjdoub, Sid Ahmed Merzouk, Mohamed Bénali, Slimane Belbraouet
-
Peiman Aliparast, Hossein B. Bahar, Ziaadin D. Koozehkanani, Jafar Sobhi, Gader Karimian
-
Ananda Prasad Panta, Ram Prasad Ghimire, Dinesh Panthi, Shankar Raj Pant
-
Sweta Sengupta, James Arocho, T. Christopher Windham